申请人:Axikin Pharmaceuticals, Inc.
公开号:US20160176857A1
公开(公告)日:2016-06-23
Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula I, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.
本文提供了3,5-二氨基吡唑类化合物,例如,具有公式I的化合物,这些化合物对调节COPD激酶活性有用,并且其药物组合物。本文还提供了它们的使用方法,用于治疗、预防或改善RC激酶介导的疾病、疾病或症状之一或多个。